Results for 'hematologic malignancy'
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Feb 22nd • 10 mins read
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
Apr 1st • 14 mins read
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Jan 20th • 20 mins read
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
Jun 7th • 8 mins read
The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
Feb 23rd • 9 mins read
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
Sep 2nd • 10 mins read
Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools
May 17th • 12 mins read
The evolving landscape of precision medicine in primary liver cancer
Mar 29th • 3 mins read
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016
Aug 4th • 15 mins read
Cancer research in the United States: A critical review of current status and proposal for alternative models
May 14th • 10 mins read